The objective of this study was to explore the molecular defects in two Chinese families with hypodysfibrinogenemia. The coagulation method and immunoturbidimetric method were used to detect plasma fibrinogen activity and plasma fibrinogen antigen. The fibrinogen genes were amplified by PCR, and suspected mutations were confirmed by reverse sequencing. Bioinformatics and model analysis were used to study the conservatism and harm of the mutations. Study showed that the Fg:C and Fg:Ag of the probands of the two families were reduced, respectively, to 0.80g/L, 0.92g/L and 1.35g/L, 1.42g/L; gene analysis revealed that the proband 1 had a heterozygous missense mutation of c.688T>G (p.γPhe230Val) in exon 7 of the FGG gene; the c.2516A>C (p.AαAsn839Thr) heterozygous missense mutation in exon 6 of the FGA gene was got by the proband 2. These mutations found in this study might be related to the hypodysfibrinogenemia.

Keywords:
Fibrinogen, Gene mutation, Hereditary hypodysfibrinogenemia
1.
Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin. 2016;74(4):405–12.
2.
Marchi R, Vilar R, Durual S, Goodyer M, Gay V, Neerman-Arbez M, et al. Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. Thromb Res. 2021;197:56–64.
3.
Peck RC, Fitzgibbon L, Reilly-Stitt C, Doherty C, Phillips E, Mumford AD. Pseudohomozygous dysfibrinogenemia. Res Pract Thromb Haemost. 2021;5(6):e12568.
4.
Zhou P, Yu M, Peng Y, Ma P, Wan L. Identification and characterization of novel mutations in Chinese patients with congenital fibrinogen disorders. Blood Cells Mol Dis. 2021;86:102489.
5.
Medved L, Weisel JW; Fibrinogen and Factor, XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis, XSoSSCoISoT Factor, Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost. 2009;7(2):355–9.
6.
Casini A, Undas A, Palla R, Thachil J, de Moerloose P; Subcommittee on Factor XIII an, d Fibrinogen, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1887–90.
7.
Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature. 1997;389(6650):455–62.
8.
Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 2011;31(3):494–9.
9.
Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:11–30.
10.
Kotlin R, Pastva O, Stikarova J, Hlaváčková A, Suttnar J, Chrastinova L, et al. Two novel mutations in the fibrinogen gamma nodule. Thromb Res. 2014;134(4):901–8.
11.
Zhu L, Wang Y, Zhao M, Hao X, Xie H, Xie Y, et al. Novel mutations (γTrp208Leu and γLys232Thr) leading to congenital hypofibrinogenemia in two unrelated Chinese families. Blood Coagul Fibrinolysis. 2014;25(8):894–7.
12.
Davis RL, Mosesson MW, Kerlin BA, Canner JA, Ruymann FB, Brennan SO. Fibrinogen Columbus: a novel gamma Gly200Val mutation causing hypofibrinogenemia in a family with associated thrombophilia. Haematologica. 2007;92(8):1151–2.
13.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8.
14.
Protopopova AD, Litvinov RI, Galanakis DK, Nagaswami C, Barinov NA, Mukhitov AR, et al. Morphometric characterization of fibrinogen's αC regions and their role in fibrin self-assembly and molecular organization. Nanoscale. 2017;9(36):13707–16.
15.
Tang H, Fu Y, Zhan S, Luo Y. Alpha(E)C, the C-terminal extension of fibrinogen, has chaperone-like activity. Biochemistry. 2009;48(18):3967–76.
16.
Zhou L, Nho K, Haddad MG, Cherepacha N, Tubeleviciute-Aydin A, Tsai AP, et al. Rare CASP6N73T variant associated with hippocampal volume exhibits decreased proteolytic activity, synaptic transmission defect, and neurodegeneration. Sci Rep. 2021;11(1):12695.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.